Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives

Osteosarcoma (OS) is an aggressive osteoid-producing tumor of mesenchymal origin, which represents the most common primary bone malignancy. It is characterized by a complex and frequently uncertain etiology. The current standard care for high-grade OS treatment is neoadjuvant chemotherapy, followed...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercatelli, Daniele, Bortolotti, Massimo, Bazzocchi, Alberto, Bolognesi, Andrea, Polito, Letizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874676/
https://www.ncbi.nlm.nih.gov/pubmed/29439419
http://dx.doi.org/10.3390/biomedicines6010019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874676/
https://www.ncbi.nlm.nih.gov/pubmed/29439419
http://dx.doi.org/10.3390/biomedicines6010019

Ejemplares similares